Ahmedabad: With a powerful enhanced search tool and streamlined navigation, India’s leading pharmaceutical enterprise, Cadila Pharmaceuticals, today announced the launch of its completely revamped, next-generation official website. Designed with a modern, intuitive interface, the new platform delivers seamless navigation and accelerated performance for patients, healthcare professionals, global partners, and job seekers across desktop, tablet, and smartphone devices.

In the AI era and built for speed and clarity, the transformed portal (www.cadilapharma.com) features an intelligent AI-powered chatbot that offers instant assistance, helping users discover products, services, and career information in just a few clicks. With a powerful enhanced search tool and streamlined navigation, visitors can effortlessly explore Cadila’s comprehensive portfolio across major therapeutic areas including Gastroenterology, Oncology, Cardiology, and Diabetology alongside its Active Pharmaceutical Ingredients (APIs) and CDMO partnerships.

Commenting on the digital launch, Jatin Shah, COO, Generics & Institution Business, Cadila Pharmaceuticals Ltd., said, “As we build on our legacy of over seven decades, adapting AI-powered technology into our digital ecosystem reflects our unwavering commitment to healthcare innovation. This revamped platform is thoughtfully designed to make key information accessible, fast, and transparent for all our stakeholders. By leveraging modern digital tools, we continue to reinforce our mission of delivering trusted, high-quality healthcare solutions that improve lives globally.”

Every section of the new website highlights Cadila’s cutting-edge R&D capabilities, global footprint, and enduring legacy of trust. The portal also introduces an enhanced ‘Life at Cadila’ section, reflecting a workplace culture grounded in innovation, learning, and collaboration. As a Great Place to Work® certified organization, the platform offers job seekers a clear gateway to explore meaningful career opportunities and build a purposeful future.

About Cadila Pharmaceuticals – www.cadilapharma.com

Cadila Pharmaceuticals is one of India’s largest privately held pharmaceutical companies with a global presence across formulations, active pharmaceutical ingredients (APIs), biologics, consumer healthcare, and specialty products. The company operates state-of-the-art manufacturing facilities and serves patients across multiple international markets through its commitment to quality, innovation, and affordability.

The post Cadila Launches Next-Generation Official Website appeared first on Health Vision.

Objective of the Competitions
The competitions aim to communicate important health messages to society in a creative and impactful manner through cartoons and photographs. Participants can highlight themes such as healthy lifestyles, cleanliness and sanitation, pollution control, the harmful effects of smoking and alcohol consumption, yoga and exercise, nutritious food, public health services, and the ground realities of hospitals and healthcare.
Who Can Participate?
Cartoon Competition:
All cartoonists, doctors, healthcare professionals, medical and paramedical students.
Photography Competition:
Photographers, doctors, healthcare professionals, medical students and amateur photographers.
Major Themes
Participants may choose subjects including:
• Health problems and diseases
• Environmental health
• Cleanliness and sanitation
• Yoga and exercise
• Healthy and nutritious food
• Awareness against smoking, alcohol and substance abuse
• Health awareness programmes
• Hospitals and the services of healthcare workers
• Any other creative subject related to health and public awareness
General Rules
• Each participant can submit a maximum of 3 entries in each competition.
• All cartoons and photographs must be original works created/taken by the participant and must not have been published previously.
• Cartoons should be in A4/A3 size at 300 DPI. Photographs should be submitted in high-quality JPEG/PNG format.
• A 2–3 line description explaining the theme/message of each entry is mandatory.
• Participants must provide their name, complete address, mobile number and passport-size photograph.
• All cartoons and photographs must be submitted only through email.
Prizes
Each competition will have First, Second and Third Prizes, along with two Consolation Prizes.
Winners will be honoured with prizes, awards and certificates. All selected cartoons and photographs will be considered for publication in Vydyaloka, one of Karnataka’s leading health magazines.
A Great Opportunity – Don’t Miss It!
This is a wonderful opportunity for artists, photographers, doctors, healthcare professionals and students to showcase their creativity while spreading an important message about health and well-being.
Your creativity can inform, inspire and create a positive impact on society. Showcase your talent, create health awareness and make a difference!
Don’t Miss This Opportunity!
Participate in the Vydyaloka Cartoon and Photography Competitions – 2026 and let your creativity inspire a healthier society.
Last Date for Submission
31 August 2026
The last date for submitting entries for both competitions is 31 August 2026.
“Spread the message of health to society through your pen and camera!”
Organisers
Karnataka Arogya Sahitya Parishat
Bengaluru Health Foundation
Submission Details
Email: mediaicon@ymail.com
For More Information
Shrikrishna M: 81975 54373

The post Vydyaloka Cartoon and Photography Competitions – 2026 appeared first on Health Vision.

The exclusive dermo-focused symposiums will feature the latest advances in regenerative dermatology, nanotechnology, and science-backed skincare
New Delhi, August 10, 2026: Sesderma Founder and renowned Spanish dermatologist Professor Dr. Gabriel Serrano is visiting India to participate in exclusive scientific symposiums hosted by Iberia Pharmaceuticals. The symposiums, scheduled to take place in New Delhi and Hyderabad, will bring together the country’s dermatology community for meaningful discussions and an exchange of scientific knowledge and insights.
The ‘Grand Dermatology Symposiums’ will bring together pharma skincare industry stakeholders including leading dermatologists, and key opinion leaders to explore the latest advancements in dermatological science and innovation. At the symposiums, Professor Dr. Gabriel Serrano will share insights into the regenerative dermatology, nanotechnology-based dermo-cosmetics, micro-needling technologies, skin longevity, healthy skin ageing and chemical peels tailored to the Indian skin photo types. The symposiums will focus on key global advancements in:
Professor Dr. Gabriel Serrano will discuss emerging approaches to skin and body regeneration, including the growing role of regenerative medicine in skincare. He will also highlight innovative technologies and devices designed to enable more precise and effective skin treatments. Explaining the advanced skin peels, he will share his insights how they are developed to address the specific needs of Indian skin.
Widely known for being the pioneer in the application of nanotechnology in dermatology and for developing specialized skincare and cosmetic solutions, Professor Dr. Gabriel Serrano brings decades of expertise to these discussions. He holds several patents in anti-ageing skincare, chemical peels and sun-damage repair. He founded Sesderma with a vision to provide advance personalized, high-quality dermo-cosmetic solutions through research and innovation. Currently, he focuses on expanding Sesderma’s presence internationally, with the brand now available in more than 80 countries.
Speaking on his upcoming visit to India, Professor Dr. Gabriel Serrano says “I have always been committed to innovation and research, and I firmly believe that continuing to develop effective products and treatments is the only way to deliver the best. India’s dynamic skin profiles with growing demand for science-backed skincare makes for an exciting chapter ahead. The symposiums will provide an inspiring opportunity to collaborate with the dermatologist communities in India. I look forward to engaging with India’s medical community and sharing the latest developments in regenerative medicine, nanotechnology, and personalized skincare.”
As India’s dermatology and dermo- cosmetic sector is experiencing positive and a welcome shift towards evidence-based, and science-backed solutions for skincare, Sesderma, a global dermatology company, is growing its presence in India through increased engagement with India’s dermatology community, and continued investments in research & innovations for the Indian skin.
On the partnership with Sesderma, Mr. Nitin Jain, Founder and Managing Director, Iberia Pharmaceuticals, says, “The Indian youth is increasingly seeking skin care products backed by science-based formulations, and we at Iberia firmly believe that bringing world-class skincare solutions to India is key to this new wave of demand. Our partnership with Sesderma is built on a shared commitment to scientific excellence, innovation, and delivering advanced derma-tech in India.”
Iberia Pharmaceuticals being the official and exclusive partner for Sesderma in India, plays a significant role in boosting the brand’s growth in the country, and with its strong penetration in dermatology ecosystem, the market knowledge, and nationwide distribution capabilities, the company is leading the expansion of Sesderma across evolving markets including the Tier-II cities in India.
Commenting on the symposiums, Mr. Saurav Ojha, Co-Founder & Whole-Time Director at Iberia Pharmaceuticals says “At Iberia Pharmaceuticals, our aim has primarily been to bring the best of global dermatological science-backed skincare to India that addresses the unique needs of the Indian skin. The symposiums hosted by us for the celebrated Professor Dr. Gabriel Serrano provides a powerful knowledge exchange platform to India’s dermatological community.”
India’s increasing demand for science backed skincare, and deeper adoption of clinically certified dermo-cosmetic solutions, we are expanding our footprint beyond metropolitan markets to Tier-II cities, making advanced skincare innovations more accessible to people nationwide.
About Sesderma
Founded in Spain by renowned dermatologist Professor Dr. Gabriel Serrano, Sesderma is a globally recognized dermatology and skincare company with more than 35 years of experience in science-led skin health and innovation. The company is known for its research-driven approach, with expertise spanning nanotechnology, advanced drug delivery systems, regenerative dermatology and dermo cosmetics. Sesderma develops solutions that combine dermatological science and innovative technologies to address evolving skin health needs across diverse skin types. Today, the brand has a presence in markets worldwide and continues to advance its focus on science-backed, clinically oriented skincare.
About Iberia Pharmaceuticals
Iberia Pharmaceuticals is a leading name in pharmaceutical innovation, dedicated to developing scientifically advanced solutions in skin, hair health and cardio diabetic care. Their portfolio features trusted brands recognized for their clinically proven formulations and pharmaceutical backed expertise. The company has a line of safe, effective skincare products along with cardio-diabetic care that address real concerns of Indian skin & wellness. With a strong commitment to innovation and clinical excellence, Iberia seeks to ensure that every product meets the highest industry standards and delivers effective, results driven care.

The post Professor Dr. Gabriel Serrano to Visit India at Symposiums appeared first on Health Vision.

Ahmedabad: Cadila Pharmaceuticals has reiterated that there is no order prohibiting the manufacture, sale or distribution of its Aciloc 150+ and Aciloc 300+ products. The company continues to comply with all applicable national regulatory requirements and supplies to pharmacies continue uninterrupted.

Cadila Pharmaceuticals reaffirmed that the active pharmaceutical ingredient has always been clearly and prominently declared on the packaging and labels of all Aciloc products in accordance with applicable labelling requirements. The company’s scientific and regulatory teams are engaging with the relevant authorities and examining the matter in detail.

The company clarified that Aciloc 150+ and Aciloc 300+ contain Famotidine, a well-established H2 receptor antagonist with a favourable pharmacokinetic profile, an excellent safety record and a rapid onset of action that provides prompt relief from acid-related symptoms. The respective active ingredients are clearly identified on every pack.

Dr. Arani Chatterjee, President, Cadila Pharmaceuticals Limited, said, “Patient safety remains our highest priority. The active pharmaceutical ingredient is clearly stated on every Aciloc pack in accordance with applicable regulatory requirements. We are working closely with the relevant authorities and extending our full cooperation while reviewing the matter carefully. We remain committed to ensuring continued confidence in the quality, safety and appropriate use of our medicines, while continuing to ensure uninterrupted availability of our products.”

For more than 75 years, Cadila Pharmaceuticals has been a pioneer in the Indian healthcare industry, developing high-quality, affordable medicines while adhering to applicable regulatory standards, robust quality systems and ethical business practices.

Cadila Pharmaceuticals reiterated its commitment to the highest standards of quality, patient safety and regulatory compliance, and said it will continue to work constructively with the relevant authorities.

About Cadila Pharmaceuticals:
Cadila Pharmaceuticals is one of India’s largest privately held pharmaceutical companies with a global presence across formulations, active pharmaceutical ingredients (APIs), biologics, consumer healthcare, and specialty products. The company operates state-of-the-art manufacturing facilities and serves patients across multiple international markets through its commitment to quality, innovation, and affordability.

The post Cadila clarifies position on Aciloc range – reiterates commitment appeared first on Health Vision.

Mumbai: Cadila Pharmaceuticals, a leading research-driven pharmaceutical company, has reaffirmed its commitment to patient safety following a recent regulatory communication concerning its Aciloc range.

Cadila Pharmaceuticals reiterated that the active pharmaceutical ingredient has always been clearly and prominently declared on the packaging and labels of all Aciloc products in accordance with applicable regulatory requirements. The company’s scientific and regulatory teams are engaging with the relevant authorities and examining the matter in detail.

Dr. Arani Chatterjee, President, Cadila Pharmaceuticals Limited, said, “Patient safety remains our highest priority. The active pharmaceutical ingredient is clearly stated on every Aciloc pack in accordance with applicable regulatory requirements. We are working closely with the relevant authorities, extending our full cooperation and reviewing the matter carefully. We remain committed to ensuring continued confidence in the quality, safety and appropriate use of our medicines.”

The company further clarified that Aciloc 150+ and Aciloc 300+ belong to the same therapeutic class of H2 receptor antagonists, with the respective active ingredients clearly identified on every pack in accordance with regulatory requirements.

For more than 75 years, Cadila Pharmaceuticals has been a pioneer in the Indian healthcare industry, developing high-quality, affordable medicines while adhering to applicable regulatory standards, robust quality systems and ethical business practices.

Cadila Pharmaceuticals reiterated that it remains committed to maintaining the highest standards of quality, patient safety and regulatory compliance, and will continue to work constructively with the relevant authorities.

About Cadila Pharmaceuticals

Cadila Pharmaceuticals is one of India’s largest privately held pharmaceutical companies with a global presence across formulations, active pharmaceutical ingredients (APIs), biologics, consumer healthcare, and specialty products. The company operates state-of-the-art manufacturing facilities and serves patients across multiple international markets through its commitment to quality, innovation, and affordability.

The post Cadila reaffirms commitment to patient safety appeared first on Health Vision.

Sathya Sai Grama, Karnataka: The Sri Madhusudan Sai Institute of Medical Sciences and Research (SMSIMSR), the India’s first free private rural medical college under the One World One Family Mission, concluded the two-day International Endoscopic & Robotic Cardiac Surgery Conference (IERCSC 2026), bringing together leading cardiac surgeons, researchers and academicians from across the world to advance innovation in minimally invasive and robotic heart surgery.

Organised by SMSIMSR under the One World One Family Mission, in association with Manipal Hospitals and SS Innovations, the conference attracted renowned cardiac surgeons, medical professionals and students from India, the United States, Greece, Germany, Brazil, China, Vietnam, Malaysia, Ukraine and several other countries. The event served as a global platform for exchanging knowledge, showcasing advanced surgical techniques and strengthening international collaboration in cardiac surgery.

A major highlight of the conference was the successful demonstration of live remote robotic cardiac surgery. Dr. Sudhir Srivastava, Founder and Chairman of SS Innovations, remotely performed a complex robotic cardiac procedure from Delhi on a patient at SMSIMSR using the indigenous SSI Mantra robotic platform. Live surgical transmissions from Coimbatore and Greece also enabled delegates to interact with operating teams in real time. All the patients are recovering well.

The conference featured scientific sessions on the latest advances in endoscopic and robotic cardiac surgery, including robotic valve replacement, valve repair, coronary artery bypass surgery and minimally invasive procedures. Surgeons from leading hospitals and universities across the world exchanged experiences and discussed technologies that are reshaping the future of cardiac care.

The second day was devoted to hands-on surgical training, with more than 100 senior cardiac surgeons receiving practical training in endoscopic and robotic cardiac surgery using bovine and porcine heart models under the guidance of international experts. The programme provided participants with practical exposure to advanced surgical techniques that are currently available only at a limited number of centres globally. Another highlight of the conference was the panel discussion on “How India Can Become a Global Hub for Endoscopic and Robotic Cardiac Surgery Training.” Experts emphasised the need to strengthen specialised training, promote indigenous innovation and expand access to robotic surgery.

Organisers noted that comparable international training programmes typically cost between ₹18 lakh and ₹20 lakh, whereas the entire programme at SMSIMSR, under the One World One Family Mission, was offered completely free of charge. To strengthen long-term academic collaboration, SMSIMSR, Manipal Hospitals, Kolkata, and SS Innovations signed a Memorandum of Understanding (MoU) to organise the conference once every two years and jointly promote education, research and training in endoscopic and robotic cardiac surgery.

Addressing the gathering, Sadguru Sri Madhusudan Sai, Founder of the One World One Family Mission and SMSIMSR said medical education should nurture compassionate doctors alongside skilled clinicians. “Ten years ago, this region had very limited infrastructure. Today, it has evolved into a global centre for medical education, research and rural healthcare. Through the One World One Family Mission, we remain committed to making world-class medical education and healthcare accessible to everyone, irrespective of their financial background,” he said.

Speaking at the conference, Dr. C. S. Hiremath, Organising Secretary, said the objective was to create an international academic platform where surgeons could learn directly from global experts while gaining practical exposure to advanced surgical technologies. Dr. Sudhir Srivastava said indigenous robotic technology has the potential to transform cardiac care by making advanced procedures more accessible and affordable.

Highlighting the impact of indigenous innovation, Dr. Nitin Rajput, one of the first surgeons to perform cardiac surgery using the Indian-developed SSI Mantra robotic system, said affordability would be the biggest driver of wider adoption. The conference concluded with a shared commitment among leading surgeons and institutions to expand global collaboration, strengthen surgical education and accelerate the adoption of endoscopic and robotic technologies. Organisers said the entire conference and advanced surgical training programme were offered free of charge by the One World One Family Mission, reaffirming its commitment to making world-class medical education and cutting-edge healthcare accessible to all.

The post Can Rural India Lead the Future of Robotic Heart Surgery? appeared first on Health Vision.

Ahmedabad: Eva Women’s Hospital today marked a defining milestone in advanced Healthcare for women, especially in gynaecology and gynaec oncology, with the installation of the ‘DA VINCI XI’ Surgical System, one of the world’s most sophisticated robotic-assisted surgical platforms. The introduction of this cutting-edge technology reinforces the hospital’s commitment to delivering safer, more precise and minimally invasive gynaecological care.

Designed to enhance a surgeon’s capabilities rather than replace them, the DA VINCI XI Surgical System combines high-definition 3D visualization, wristed instruments and enhanced precision to assist in performing complex gynaecological procedures with greater accuracy. Technology is particularly beneficial in treating deep infiltrating endometriosis, gynaecological cancers and other complex pelvic conditions, enabling meticulous nerve-sparing surgery through minimally invasive techniques. This can potentially reduce blood loss, post-operative pain, wound-related complications and hospital stay, while supporting faster recovery and improved patient outcomes, including in complex cases such as obese patients with endometrial cancer.

The technology will be led by Dr. Dipak Limbachiya, M.D., D.G.O., Laparoscopy & Robotic Surgeon, Advanced Gynaecological and Gynaec Oncology Surgeon, and Founder Director of Eva Women’s Hospital, who has widely been recognised as ‘Lapguru’ for his pioneering contributions to minimally invasive gynaecological surgery. Guided by the belief that every woman deserves access to the safest and most advanced surgical care, Dr. Limbachiya has dedicated his career to making complex procedures less invasive. For many women, particularly mothers and caregivers, faster recovery means returning sooner to their families, responsibilities and the lives they cherish, a vision that the DA VINCI XI Surgical System is designed to support.

“Every woman deserves access to the safest and most advanced surgical care available. Behind every procedure is a daughter, a mother, a wife or a professional eager to regain her health and return to life with confidence. Our decision to introduce the DA VINCI XI Surgical System is rooted in that belief. As India’s healthcare landscape continues to embrace advanced robotic-assisted surgery, we are proud to bring this global innovation to women in Gujarat through compassionate, patient-centric care,” said Dr. Dipak Limbachiya.

The inauguration of the DA VINCI XI Surgical System marks another significant chapter in Eva Women’s Hospital’s journey of clinical excellence, reaffirming its commitment to combining world-class technology with compassionate care and setting new benchmarks for robotic-assisted gynaecological surgery in India.

About Eva Women’s Hospital:

EVA has developed a strong reputation for managing complex gynecological oncological medical conditions with precision EVA specializes in a comprehensive range of minimally invasive surgical procedures, providing safer alternatives to traditional open surgeries. EVA’s surgical expertise spans Total Laparoscopic Hysterectomy (TLH), Laparoscopic Wertheim’s Hysterectomy, Laparoscopic Extra Fascial Hysterectomy, Completion Hysterectomy, and Myomectomy. advanced medical care, offering them the best solutions for their reproductive, hormonal, and oncological needs.

The post DA VINCI XI advanced Robotic-Assisted Surgical System appeared first on Health Vision.

Ahmedabad – Cadila Pharmaceuticals, one of India’s leading integrated pharmaceutical companies, and Wellesta Holdings Pte. Ltd., Singapore, have signed a Memorandum of Understanding (MoU) to establish a strategic Joint Venture aimed at expanding access to high-quality healthcare solutions across South-East Asia and selected international markets. The partnership brings together the complementary strengths of both organizations.

Cadila Pharmaceuticals contributes its extensive capabilities in research & development, manufacturing, regulatory compliance, and a diversified portfolio spanning prescription medicines, consumer healthcare products, and specialty therapies. With decades of pharmaceutical expertise and a strong vertically integrated business model, Cadila has established itself as a trusted healthcare partner across multiple global markets.

Wellesta Holdings, headquartered in Singapore, is a fast-growing healthcare and pharmaceutical commercialization company with a strong presence across South-East Asia and other international markets. Through its established front-end infrastructure, market access capabilities, regulatory expertise, distribution network, and experienced commercial teams, Wellesta has successfully built and managed numerous healthcare partnerships across the region.

The proposed Joint Venture will focus on identifying and commercializing high-potential pharmaceutical and healthcare products, leveraging Cadila’s innovation and manufacturing excellence together with Wellesta’s market reach and commercialization strengths. The collaboration is expected to strengthen Cadila’s presence in key growth markets while enhancing Wellesta’s portfolio with differentiated and high-quality healthcare solutions.

The Joint Venture is envisioned as a strategic growth engine to expand business across South-East Asia, the Middle East, Africa, and other emerging markets. By combining Cadila’s product development and supply capabilities with Wellesta’s strong regional commercial footprint, the partnership aims to build a significant healthcare business over the coming years.

This collaboration reflects the shared commitment of both companies to improving healthcare outcomes through innovation, quality, and market excellence, while creating lasting value for patients, healthcare professionals, partners, and stakeholders.

The post Cadila & Wellesta Holdings Singapore Sign Strategic Joint Venture appeared first on Health Vision.

Ahmedabad, Gujarat: Ahmedabad consumers can now access home diagnostic sample collection within 30 minutes, as Sterling Accuris launches Accuris Express, a new service designed to bring greater speed, convenience, and responsiveness to diagnostic testing. The service is being launched in Ahmedabad initially, with plans for a phased expansion across Gujarat.

The launch comes at a time when consumer expectations are increasingly being shaped by on-demand services that prioritise speed, predictability, and doorstep delivery. While these expectations have transformed several consumer categories, diagnostic testing has traditionally operated within broader collection windows and uncertain waiting periods.

With Accuris Express, Sterling Accuris aims to simplify access to diagnostics by enabling quicker sample collection at home, reducing the inconvenience often associated with laboratory visits and extended waiting periods.

Designed to meet the needs of today’s fast-paced lifestyles, Accuris Express combines rapid home sample collection with Sterling Accuris’ established standards of clinical excellence, safety, hygiene, and diagnostic accuracy. Through the Sterling Accuris Diagnostics Website & App, users can book eligible tests and receive priority home sample collection by trained phlebotomists within 30 minutes across Ahmedabad.

The service has been developed to support a range of healthcare needs – from unexpected health concerns and time-sensitive diagnostic requirements to routine preventive health checks. It is also expected to benefit elderly patients, caregivers, families with young children, and working professionals seeking greater convenience in accessing healthcare services.

Among the early users of the service was Ahmedabad resident Vishal Mehta, who described his blood test experience through Accuris Express as fast, reliable, accurate, and convenient—comparable to quick-commerce platforms like Zepto and Blinkit. He also expressed hope that the service would soon expand to other cities across Gujarat.

Commenting on the launch, Mr. Ankush Gupta, CEO, Sterling Accuris, said, “Consumers today can order groceries, medicines, and essential services in minutes. Yet when it comes to diagnostics, they are often asked to wait for hours. We saw a clear disconnect between evolving consumer expectations and the traditional diagnostic experience. Accuris Express has been developed to bridge that gap by making access to diagnostic testing faster, simpler, and more convenient. As healthcare increasingly moves closer to the patient, we believe services that combine clinical reliability with greater convenience will play an important role in shaping the future of diagnostics.”

Mr. Rajiv Sharma, Managing Director, Sterling Accuris, added, “For many patients, the time between recognizing a health concern and getting tested can be frustrating. Accuris Express has been designed to reduce that gap by bringing trusted diagnostic services directly to patients’ homes. While speed is a key differentiator, our commitment to clinical accuracy, quality standards, and patient safety remains unchanged.”

Initially available for select tests and locations in Ahmedabad, Accuris Express is expected to be expanded to additional service areas and cities across Gujarat over time.

Established in 2015, Sterling Accuris is one of Gujarat’s leading pathology laboratory networks, operating over 90 processing laboratories and more than 300 collection centres, with a comprehensive diagnostic portfolio of over 2,000 tests.

The launch reflects a broader shift in healthcare delivery, where convenience, accessibility, and responsiveness are becoming increasingly important components of patient experience. By combining trusted diagnostics with rapid doorstep service, Sterling Accuris aims to make timely testing more convenient and accessible for consumers across Ahmedabad.

The post 30-Minute Home Sample Collection in Ahmedabad appeared first on Health Vision.

Ahmedabad: Group Mangalam, a multinational conglomerate with a rich legacy of 8 decades has announced its foray into Indian nutraceuticals and wellness sector with the launch of NEAT EVERYDAY– its a new brand. Marking its retail debut, the brand has simultaneously opened five stores across Ahmedabad, featuring an experience center at Prernatirth Derasar Road, alongside four strategic outlets at Bodakdev, South Bopal, Memnagar (Surdhara Circle), and Nehrunagar.

This brick-and-mortar rollout aligns with ‘Neat Everyday’s long-term strategy to capture a significant share of India’s wellness economy by simplifying everyday self-care routines. The flagship store is meticulously designed to offer urban consumers an immersive, interactive, and seamless sensory shopping experience.

A Clean-Label Portfolio Rooted in Science and Purity

‘Neat Everyday’ enters the market with a robust portfolio of over 30 meticulously formulated wellness essentials. The entire range is 100% vegan, gluten-free, paraben-free, and crafted from natural ingredients. Catering to the modern consumer’s demand for functional, clean-label daily solutions, the brand’s offerings are structured across five specialized wellness pillars

• Oils (Nutrient-rich, cold-pressed formulations)
• Soft Gels/Capsules (Targeted daily health supplements)
• Ghee Capsules (Traditional wellness reimagined for modern convenience)
• Moisture and Mist (Clean-label skin and personal care essentials)
• Gummies (On-the-go nutrition designed for modern lifestyles)

Capitalizing on a Surging Wellness Market

The launch comes at a time when India’s nutraceuticals, wellness, and preventive healthcare sectors are experiencing robust growth. India’s nutraceuticals and wellness market is projected to reach approximately $30 billion by 2027, driven by rising consumer demand for preventive healthcare, clean-label products, and holistic wellness solutions. Across the country, consumers are increasingly prioritizing nutrition, immunity, and long-term well-being, fueling rapid growth in dietary supplements and wellness products. Gujarat, in particular, has emerged as a high-potential market, supported by a health-conscious consumer base and growing adoption of premium, science-backed nutraceuticals and wellness offerings.

Commenting on the landmark launch, Vipin Prakash Mangal, Chairman & Executive Director of Group Mangalam, “Our entry into the nutraceuticals and wellness ecosystem represents a natural evolution of Group Mangalam’s 84-year-old legacy of trust. Today’s consumer, particularly in high-growth markets like Gujarat and greater India, is actively seeking transparent, science-backed solutions that seamlessly fit into their fast-paced daily routines. Neat Everyday is our answer to this demand—bridging the gap between strict purity and modern convenience. By maintaining the highest standards of clean-label innovation, this significant step will substantially enhance the quality of life for our consumers. Looking ahead, we have charted an aggressive nationwide footprint, with plans to establish more than 275 retail touchpoints across Pan-India by March 2027.”

Sharing their vision regarding the experiential retail blueprint, Honey Mangal and Tanisha Mangal, Promoter Group, NEAT Everyday, “we believe that self-care shouldn’t be complicated; it should be intuitive, honest, and accessible. Our debut stores in Ahmedabad are not just transactional spaces, they are experiential discovery centers. We have intentionally designed an interactive environment where customers can touch, feel, and understand the science behind our cold-pressed and vegan formulations. Our objective is to solve real-life lifestyle friction points, building deep, lasting relationships with our community and establishing Neat Everyday as the ultimate destination for contemporary wellness and daily essentials.“

The Road Ahead

As part of its sustained capital deployment and expansion roadmap, Neat Everyday will continue to deepen its penetration in Tier-1 and Tier-2 urban markets across India, backed by a robust omni-channel ecosystem via its digital commerce portal, www.neateveryday.com. The brand remains committed to introducing continuous product innovations tailored specifically to the evolving physiological and lifestyle needs of modern Indian households.

About NEAT EVERYDAY:

Neat Everyday is the specialized nutraceuticals & wellness division of Group Mangalam, an industrial pioneer and trusted conglomerate known across India for its uncompromising strength, integrity, and quality since 1942. Built on the core ethos of providing “clean, honest, and functional daily solutions,” Neat Everyday blends decades of legacy sourcing expertise with modern biomedical research to deliver premium, plant-based self-care essentials for the global consumer.

The post Group Mangalam Enters Nutraceuticals & Wellness Sector appeared first on Health Vision.